Evolution Wealth Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Evolution Wealth Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-88	Closed	-$14K	–	179
2021 Q3	$14K	Sell	88 -123	-58%	-$16.8K	﹤0.01%	359
2021 Q2	$28K	Hold	211	–	–	0.01%	261
2021 Q1	$27K	Buy	211 +8	+4%	+$1.22K	0.01%	256
2020 Q4	$34K	Sell	203 -33	-14%	-$5.46K	0.01%	208
2020 Q3	$36K	Buy	236 +25	+12%	+$3.59K	0.01%	210
2020 Q2	$31K	Sell	211 -15	-7%	-$2.06K	0.01%	169
2020 Q1	$25K	Buy	226 +36	+19%	+$4.68K	0.01%	141
2019 Q4	$26K	Buy	+190	New	+$21.1K	0.01%	200

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Evolution Wealth Advisors's ASND Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Ascendis Pharma A/S (ASND) in Q4 2021, closing a stake of 88 shares — an estimated $14K sold.

Evolution Wealth Advisors first reported a position in ASND in Q4 2019 and held it in 8 quarters. The position peaked at $36K in Q3 2020. 172 funds tracked by Wall St. Rank hold ASND as of Q4 2021.

Evolution Wealth Advisors reported no remaining Ascendis Pharma A/S position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 88 Ascendis Pharma A/S shares in Q4 2021, an estimated $14K.
Evolution Wealth Advisors first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 8 quarters.
Evolution Wealth Advisors's Ascendis Pharma A/S position peaked at $36K in Q3 2020.
172 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.